V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008968 | 330005758 | 0 | 126 | Palliative (P) | 2014-12-31 | 2015-02-09 | Capecitabine + Oxaliplatin 21day | null | null | 330023454 | LENALIDOMIDE |
| 330008969 | 330005758 | 1.59 | 72.75 | Palliative (P) | 2016-10-31 | 2016-11-02 | Capecitabine + Streptozocin | 2 | N | 330023454 | AXITINIB |
| 330008971 | 330005761 | null | 35.6 | Disease modification (D) | 2013-08-02 | 2013-10-23 | Bortezomib (weekly) | null | null | 330023516 | CARBOPLATIN + VINCRISTINE |
| 330008972 | 330005761 | 1.61 | null | Disease modification (D) | 2013-11-02 | 2013-12-14 | CNS LGG 2004 03 vinc weekly+ carbo | N | null | 330023516 | DOXORUBICIN + HD MTX |
| 330008973 | 330005762 | 1.62 | 13.2 | Neo-adjuvant (N) | 2016-08-01 | 2016-09-19 | BORTEZOMIB + THALIDOMIDE | N | N | 330023525 | CODOX M |
| 330008974 | 330005763 | 1.73 | 80.2 | Neo-adjuvant (N) | 2015-03-21 | 2015-03-24 | Hydroxycarbamide | N | N | 330023532 | BUSULFAN + MELPHALAN |
| 330008975 | 330005763 | 1.58 | 40.1 | Curative (C) | 2016-06-19 | 2016-06-19 | EVEROLIMUS | 02 | N | 330023532 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330008976 | 330011970 | 0 | 77 | Curative (C) | 2013-08-14 | 2013-09-10 | CYCLOPHOSPHAMIDE + THALIDOMIDE | N | N | 330023539 | IFOSFAMIDE |
| 330008977 | 330005766 | null | 92.2 | Curative (C) | 2017-07-15 | 2017-07-18 | PONATINIB | 02 | N | 330023548 | RUXOLITINIB |
| 330008978 | 330010965 | 1.11 | 40.3 | Not known (9) | 2014-03-07 | 2014-03-07 | Carboplatin + Docetaxel | N | null | 330023561 | FLUDARABINE + MELPHALAN |
| 330008979 | 330005770 | 1.84 | 63 | Palliative (P) | 2017-03-25 | 2017-03-25 | Fludarabine + Melphalan RIC Allo | N | N | 330023573 | CYTARABINE + RITUXIMAB |
| 330008980 | 330005771 | 1.79 | 80 | Palliative (P) | 2013-07-25 | 2013-07-30 | CYTARABINE | 02 | N | 330023606 | CVD |
| 330008981 | 330005772 | null | 80 | Curative (C) | 2013-05-13 | 2013-05-13 | R Chlorambucil | 02 | N | 330023614 | DHAP |
| 330008982 | 330005772 | 1.83 | 60 | Palliative (P) | 2017-05-17 | 2017-10-06 | AML18 PILOT TRIAL | N | N | 330023614 | CETUXIMAB + CISPLATIN + FU |
| 330008983 | 330005773 | 1.53 | 53.35 | Palliative (P) | null | 2014-04-15 | CLADRIBINE | N | N | 330023624 | EMA/CO |
| 330008984 | 330012551 | 1.85 | 80.1 | Disease modification (D) | 2017-04-01 | 2017-04-01 | LIPOSOMAL DAUNORUBICIN | N | N | 330023646 | FCR |
| 330008985 | 330005774 | 1.64 | null | Palliative (P) | null | 2013-07-08 | VIDE | N | N | 330023647 | UKALL 2011 |
| 330008986 | 330011972 | 1.76 | 54.1 | Curative (C) | null | 2019-03-06 | Ifosfamide | null | N | 330023657 | RUXOLITINIB |
| 330008987 | 330005775 | 1.65 | 64.5 | Palliative (P) | 2014-05-09 | 2014-05-09 | EMA | N | N | 330023661 | MELPHALAN + TREOSULPHAN |
| 330008988 | 330005776 | 0 | 85.7 | Curative (C) | 2016-12-08 | 2016-12-08 | Ifosfamide | 2 | N | 330023669 | CLADRIBINE |
| 330008989 | 330005778 | 1.55 | 10.8 | Curative (C) | 2014-12-30 | 2014-12-30 | Bevacizumab 5mg/kg | 02 | N | 330023693 | IBRUTINIB |
| 330008990 | 330005779 | 1.6 | 56.8 | Palliative (P) | 2014-01-27 | 2014-01-30 | Cytarabine Low Dose | 02 | N | 330023705 | DACTINOMYCIN + CYCLO + VINCRISTINE |
| 330008991 | 330009151 | 1.6 | 56.5 | Palliative (P) | 2018-05-13 | 2018-07-19 | BUSULFAN + MELPHALAN | 01 | N | 330023705 | CLADRIBINE |
| 330008992 | 330012880 | 0 | 62.1 | null | 2017-05-20 | 2017-05-25 | Cytarabine Low Dose | N | N | 330023722 | IFOSFAMIDE |
| 330008993 | 330009152 | 0 | 55 | Neo-adjuvant (N) | null | 2015-10-25 | AML17 TRIAL | null | null | 330023723 | BENDAMUSTINE |
| 330008994 | 330005782 | null | null | Curative (C) | 2016-11-07 | 2016-11-07 | Triple / Double Intrathecal Therapy | N | N | 330023743 | GEMCITABINE |
| 330008995 | 330005784 | 1.6 | 23.6 | Palliative (P) | 2013-12-17 | 2013-12-17 | STS Rhabdomyosarcoma RMS 2005 IVA | 2 | N | 330023744 | VIDE |
| 330008996 | 330005786 | 1.7 | null | Curative (C) | 2012-11-30 | 2013-02-08 | Cyclophosphamide + Vincristine | N | null | 330023750 | UKALL 2003 |
| 330008997 | 330005786 | 1.69 | 96.2 | Palliative (P) | null | 2017-04-22 | Packer Maintenance Regimen | N | null | 330023750 | AML17 TRIAL |
| 330008998 | 330010970 | 1.65 | 82.3 | Palliative (P) | 2017-09-19 | 2017-09-19 | PEMBROLIZUMAB | N | N | 330023758 | VIDE |
| 330008999 | 330005787 | 0 | 86.6 | Palliative (P) | 2014-06-09 | 2014-06-09 | Bendamustine +/- Prednisolone | N | N | 330023758 | BEAM |
| 330009000 | 330005787 | 1.79 | 80 | Palliative (P) | 2016-01-17 | 2016-01-23 | CHLORAMBUCIL + DEXAMETHASONE + DEXAMETHASONE + ETOPOSIDE | 02 | N | 330023758 | CHOP R |
| 330009001 | 330005788 | null | 78.8 | Palliative (P) | 2015-01-31 | 2015-01-31 | Capecitabine (14 days)+Carboplatin | Y | null | 330023765 | CISPLATIN + VINORELBINE |
| 330009002 | 330005788 | 1.62 | 95.1 | Curative (C) | 2014-07-30 | 2014-09-09 | Pazopanib | N | N | 330023765 | EPIRUBICIN |
| 330009003 | 330005788 | 1.83 | 81.3 | Palliative (P) | 2016-08-06 | 2017-02-06 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | N | N | 330023765 | BENDAMUSTINE |
| 330009004 | 330005790 | 1.74 | 25.36 | Curative (C) | 2014-12-10 | 2014-12-18 | ALL UKALL60+ TRIAL | N | N | 330023791 | CHLORAMBUCIL + RITUXIMAB |
| 330009005 | 330005791 | 1.75 | 52.5 | Palliative (P) | 2015-09-03 | 2015-09-07 | Dacarbazine | N | null | 330023808 | CISPLATIN + GEMCITABINE |
| 330009006 | 330005792 | null | 74 | Disease modification (D) | null | 2017-04-21 | VIDE | null | null | 330023816 | CARBOPLATIN + CETUXIMAB + FU |
| 330009007 | 330005792 | null | 82 | Palliative (P) | 2014-12-06 | 2014-12-06 | Etoposide + Ifosfamide + HD Mtx | null | null | 330023816 | CHOP |
| 330009008 | 330005792 | 1.7 | 35.75 | Palliative (P) | 2013-12-07 | 2013-12-14 | CHLORAMBUCIL + prednisolone | N | N | 330023816 | CAPECITABINE |
| 330009009 | 330009159 | 1.57 | 72.7 | Palliative (P) | 2017-09-03 | 2017-09-11 | AML 19 TRIAL | 2 | N | 330023833 | VIDE |
| 330009010 | 330005795 | 1.65 | 94.4 | null | 2015-10-27 | 2015-10-28 | MYELOMA XI TRIAL | N | N | 330023842 | AXITINIB |
| 330009011 | 330005797 | 1.72 | 14 | null | 2013-06-29 | 2013-07-03 | Hydroxycarbamide | 02 | N | 330023851 | CVD |
| 330009012 | 330005799 | 1.59 | null | Curative (C) | null | 2015-02-26 | OFATUMUMAB | null | null | 330023865 | AML16 TRIAL |
| 330009013 | 330005800 | null | null | Neo-adjuvant (N) | 2016-01-24 | 2016-03-03 | Cetuximab+Cisplatin+FU (> Cycle 2) | Y | N | 330023868 | FBC |
| 330009014 | 330005805 | 1.74 | 66.1 | Palliative (P) | 2013-04-06 | 2013-04-10 | PCV | N | N | 330023874 | RMS 2005 TRIAL |
| 330009016 | 330005807 | 1.78 | 86.4 | Curative (C) | 2017-04-08 | 2017-04-11 | STS Rhabdo RMS 2005 Vin Cyclo | N | 1 | 330023886 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330009017 | 330005809 | 1.62 | 108 | Palliative (P) | 2014-03-22 | 2014-03-27 | Pazopanib | N | N | 330023886 | UKALL2014 |
| 330009018 | 330011979 | null | 57.5 | Curative (C) | null | 2017-10-16 | Cyclophosphamide High Dose | null | null | 330023914 | EPIRUBICIN |
| 330009019 | 330005810 | 0 | null | Adjuvant (A) | 2014-07-03 | 2014-12-04 | POMALIDOMIDE | N | N | 330023923 | CISPLATIN + EPIRUBICIN |